Disc Medicine (IRON) Director Bitterman Sells $425K of Stock
Key Points
- Disc Medicine, Inc. director Kevin Bitterman sold 5,312 shares on October 20, 2026, under a pre-arranged plan, leaving him with 13,257 shares.
- The stock recently traded around $79.48, sitting well above its 50-day moving average of $71.57.
- Wall Street firms recently updated their targets for the clinical-stage biotech company as the November 5 earnings date approaches.
Since the trade, $IRON is down 4.4% to date (from the $79.48 close on Oct 20, 2026).
Get Disc Medicine text alerts
We text you when insiders, Congress, analysts or big funds move on $IRON.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Disc Medicine, Inc. alert may contain errors. Disclosures
Disc Medicine, Inc. (NasdaqGM: IRON) director Kevin Bitterman sold 5,312 shares of the company on October 20, 2026, according to a Form 4 filed with the SEC. The shares were sold at a price of $79.95 each, for a total value of $424,694.40. The transaction was carried out under a pre-arranged trading plan.
IRON
Disc Medicine, Inc.
Kevin Bitterman vs. the S&P 500
Hypothetical returns from Kevin Bitterman's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Bitterman's IRON Trade
The planned sale reduced Bitterman's direct holdings by a 28.61% margin, cutting his position from 18,569 prior shares down to 13,257 shares. The stock closed at $79.48 on the day of the transaction. Form 4 filings require corporate insiders to report open-market trades and plan executions within two business days.
Other Institutional Activity in Disc Medicine
Other large funds have adjusted their stakes in the biotech firm recently. Baker Bros. Advisors grew its holdings by 12,607 shares, ending with 349,657 shares worth about $25,573,912.77. RA Capital Management, L.P. kept its position steady at 2,450,221 shares valued at $186,216,796. Vestal Point Capital, LP grew its stake by 850,005 shares, ending with 1,550,000 shares worth about $117,800,000. Atlas Venture Life Science Advisors, LLC held onto 1,513,875 shares valued at $115,054,500.
Disc Medicine, Inc. Stock Holds Steady
Shares recently traded around $79.48 as of October 21, 2026, matching their close on the trade date. The stock trades above its 50-day moving average of $71.57 and its 200-day moving average of $70.66. It sits about 20.1% below its 52-week high of $99.50 and up 98.7% from its 52-week low of $40.00.
Recent Earnings
The company reported a trailing-twelve-month net loss with an earnings per share of -$6.58 and a return on equity of -39.1%. The firm is scheduled to release its next financial results on November 5, 2026.
Insider Buying and Selling at Disc Medicine, Inc.
Earlier insider trades included transactions by Chief Operating Officer Yu Jonathan Yen-Wen and Chief Legal Officer Rahul Khara.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock around the time of the insider transaction, with firms such as BMO Capital, Morgan Stanley, Truist Securities, Wells Fargo, and Wedbush maintaining positive ratings.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical firm based in Watertown, Massachusetts, focused on developing new treatments for serious blood disorders.
Bottom Line
Investors are keeping an eye on the company's upcoming earnings report on November 5, 2026. Insider trades filed via Form 4 offer a look at how leadership manages personal holdings, though planned sales often follow pre-scheduled schedules rather than sudden shifts in outlook.
Related Filing Alerts
Source: Kevin Bitterman's Form 4 filing on $IRON (Oct 20, 2026). Written by software, not financial advice. How we make alerts